Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTEDD: Otelixizumab Multi-Dose Regimens in Type 1 Diabetes
NCT00451321Phase 2Terminated
- Sponsor
- GSK
- Start
- Jul 2006
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised trial of otelixizumab in type 1 diabetes mellitus (T1D), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Cytokine Release AE and 5 more. Started Jul 2006; status: terminated.
02
Drugs
otelixizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00451321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451321.